BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23770849)

  • 1. Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation.
    Tien SC; Chang ZF
    Oncogene; 2014 May; 33(22):2938-46. PubMed ID: 23770849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
    Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
    Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
    Tien SC; Lee HH; Yang YC; Lin MH; Chen YJ; Chang ZF
    Nat Commun; 2016 Jan; 7():10420. PubMed ID: 26783207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
    McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
    J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6.
    Zilberman Y; Ballestrem C; Carramusa L; Mazitschek R; Khochbin S; Bershadsky A
    J Cell Sci; 2009 Oct; 122(Pt 19):3531-41. PubMed ID: 19737819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.
    Deng R; Zhao X; Qu Y; Chen C; Zhu C; Zhang H; Yuan H; Jin H; Liu X; Wang Y; Chen Q; Huang J; Yu J
    Oncotarget; 2015 Apr; 6(11):9355-69. PubMed ID: 25823821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP2 mediates gp130-dependent cardiomyocyte hypertrophy via negative regulation of skeletal alpha-actin gene.
    Nakaoka Y; Shioyama W; Kunimoto S; Arita Y; Higuchi K; Yamamoto K; Fujio Y; Nishida K; Kuroda T; Hirota H; Yamauchi-Takihara K; Hirano T; Komuro I; Mochizuki N
    J Mol Cell Cardiol; 2010 Aug; 49(2):157-64. PubMed ID: 20226789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC6 is a microtubule-associated deacetylase.
    Hubbert C; Guardiola A; Shao R; Kawaguchi Y; Ito A; Nixon A; Yoshida M; Wang XF; Yao TP
    Nature; 2002 May; 417(6887):455-8. PubMed ID: 12024216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
    Kamemura K; Ito A; Shimazu T; Matsuyama A; Maeda S; Yao TP; Horinouchi S; Khochbin S; Yoshida M
    Biochem Biophys Res Commun; 2008 Sep; 374(1):84-9. PubMed ID: 18602369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction.
    Wattanathamsan O; Chantaravisoot N; Wongkongkathep P; Kungsukool S; Chetprayoon P; Chanvorachote P; Vinayanuwattikun C; Pongrakhananon V
    J Biomed Sci; 2023 Jan; 30(1):4. PubMed ID: 36639650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity.
    Han Y; Jeong HM; Jin YH; Kim YJ; Jeong HG; Yeo CY; Lee KY
    Biochem Biophys Res Commun; 2009 May; 383(1):88-92. PubMed ID: 19344692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of cyclooxygenase 2 expression by small GTPases Ras, Rac1, and RhoA.
    Chang YW; Putzer K; Ren L; Kaboord B; Chance TW; Qoronfleh MW; Jakobi R
    J Cell Biochem; 2005 Oct; 96(2):314-29. PubMed ID: 16088958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
    Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
    Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC6 and RhoA are novel players in Abeta-driven disruption of neuronal polarity.
    Tsushima H; Emanuele M; Polenghi A; Esposito A; Vassalli M; Barberis A; Difato F; Chieregatti E
    Nat Commun; 2015 Jul; 6():7781. PubMed ID: 26198811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
    Ahmed TA; Adamopoulos C; Karoulia Z; Wu X; Sachidanandam R; Aaronson SA; Poulikakos PI
    Cell Rep; 2019 Jan; 26(1):65-78.e5. PubMed ID: 30605687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the Ras/extracellular signal-regulated kinase (ERK) pathway.
    Quintanar-Audelo M; Yusoff P; Sinniah S; Chandramouli S; Guy GR
    J Biol Chem; 2011 Jul; 286(26):23102-12. PubMed ID: 21531714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.